The 7 Most Undervalued Stocks In Larry Robbins' Portfolio

The most undervalued stocks that Glenview Capital Managment owns as disclosed by the firm's most recent 13F filing.

Larry Robbins: The Suggestivist

Larry Robbins is a hedge fund manager and CEO of Glenview Capital Management. He is also well known for his quarterly letters to investors.

He began his career as an analyst at Gleacher and Company, an M&A firm. Later Robbins spent six years running long/short strategies for Leon Cooperman at Omega Advisors.

In 2001 Robbins started Glenview Capital Management which now runs several hedge funds and long-only funds. The firm invests in equities as well as bonds and holds both long and short positions. It has been reported that Glenview Capital Management's flagship fund returned 15 percent annually between 2000 to 2013.

Robbins has been described as a ‘Growth at a Reasonable Price' (GARP) investor and as a ‘multi-strategy investor'. He's said that he backs companies with predictable cash flows and recurring revenue streams. He often holds positions for significant periods, even when those positions move against him. As a result, he has earned a reputation for experiencing persistent winning and losing streaks.

While Robbins is not an activist investor, he does voice his opinions when it comes to some of his largest positions. In fact, he has said he would rather be ‘suggestivist' than activist. In this way, he has been instrumental in bringing about corporate action at Tenet Healthcare Corp THC and Community Health Systems CYH.

Below I take a closer look at Robbins' holdings as reported in the hedge fund's recent 13F SEC filing to find his most undervalued stocks.

Glenview Capital Management's Most Undervalued Holdings

On February 14th, Larry Robbins' firm Glenview Capital Management filed its quarterly Form 13F regulatory filing. The firm's stock portfolio totals $18.5 billion with 58 positions according to the latest filing. The list value of stock holdings is up 7.3 percent when compared to the last quarter. As a benchmark, the S&P 500 was up 6.1 percent over the same period.

To determine which stocks are trading below their intrinsic value, aka "fair value" I used the finbox.io Fair Value estimates. I also wanted to blend in some indication of which stocks might be ready to make a move up soon because they're popular with Wall Street analysts.

I calculated an average using the finbox.io fair value upside and analyst upside to create a blended upside which I then used to rank the most undervalued holdings.

Below are the top 7 stocks based on my calculations.

Brookdale Senior Living, Inc. BKD

Brookdale Senior Living, Inc. owns and operates senior living communities in the United States.

Larry Robbins' Glenview Capital Management holds a position in the company worth $177.0 million. This represents 1.0 percent of the firm's portfolio.

^{Source: finbox.io}

Shares of the company are down -28.2 percent over the last three months. The stock last traded at $6.89 as of Wednesday and 2 separate valuation analyses imply that there is big upside relative to its current trading price. Maybe worth taking a closer look at the company.

Meritor Inc MTOR

Meritor Inc manufactures, sells and supports integrated systems, modules, and components to original equipment manufacturers (OEMs) and the aftermarket for the commercial vehicle, transportation, and industrial sectors. Meritor was founded in 1921 and is headquartered in Troy, Michigan.

Glenview Capital Management currently owns 4,863,111 shares of MTOR which represents 0.6 percent of the hedge fund's stock portfolio.

^{Source: finbox.io}

Shares of Meritor are down -8.0 percent over the last three months and finbox.io's fair value estimate of $35.87 per share calculated from eight cash flow models imply 59.2 percent upside. The average price target from nine Wall Street analysts of $30.56 per share similarly imply nice upside potential.

CVS Health Corp CVS

CVS Health Corp, together with its subsidiaries, provides integrated pharmacy health care services and also sells general retail merchandise. The company entered into a definitive merger agreement to acquire Aetna Inc AET for $67.9 billion on December 3rd, 2017. As of March 13th, Aetna and CVS shareholders approved the merger and the transaction is expected to close in the second half of 2018.

Mr. Robbins currently holds a position in CVS Health Corp worth $494.6 million or 2.7 percent of his holdings.

^{Source: finbox.io}

CVS Health Corp's stock currently trades at $63.00 per share as of Wednesday, down -12.4 percent over the last three months. It's important to note that the Aetna merger is expected to be accretive to earnings in the second full year after the close of the transaction. On a standalone basis, finbox.io's seven valuation analyses suggest that shares could increase 39.9 percent going forward.

Shire PLC (ADR) SHPG

Shire PLC (ADR), a biotechnology company, researches, develops, licenses and distributes specialist medicines for people with rare diseases and other specialized conditions worldwide. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Glenview Capital Management currently owns shares of Shire worth $890.2 million. This represents the firm's fourth largest position.

^{Source: finbox.io}

Shares of the biotechnology company are trading -17.5 percent lower over the prior three months. However, the stock price could end up trading 38.9 percent higher in 2018 based on Shire's future cash flow projections.

Platform Specialty Products Corp PAH

Platform Specialty Products Corp produces and sells specialty chemical products worldwide. It operates through two segments, Performance Solutions and Agricultural Solutions. The company was founded in 1922 and is headquartered in West Palm Beach, Florida.

Larry Robbins is currently long the stock as revealed in his firm's most recent 13F filing with a position worth more than $140 million.

^{Source: finbox.io}

Platform Specialty Products' stock currently trades at $10.40 per share as of March 21st, up 3.8 percent over the last three months. On a fundamental basis, the company's stock is trading at a 35.9 percent discount to finbox.io's intrinsic value estimate. Wall Street analysts estimate that there's even more upside than that.

CIGNA Corporation CI

CIGNA Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The insurance provider was founded in 1792 and is headquartered in Bloomfield, Connecticut.

Glenview Capital Management currently holds a position worth $531.9 million or 2.9 percent of its portfolio.

^{Source: finbox.io}

Shares of the company are down -20.4 percent over the last three months. The stock last traded at $167.94 as of Wednesday and three separate valuation analyses imply that there is 48.7 percent upside relative to its current trading price.

Comcast Corporation CMCSA

Comcast Corporation operates as a media and technology company worldwide, was founded in 1963 and is headquartered in Philadelphia, Pennsylvania. The company made an offer to acquire SKY PLC SKY from Twenty-First Century Fox Inc FOXA and others for £21.5 billion on February 27th, 2018.

Mr. Robbins currently holds a position in Comcast worth $110.6 million.

^{Source: finbox.io}

Shares of Comcast are down -11.3 percent over the last three months and finbox.io's fair value estimate of $44.40 per share calculated from 12 cash flow models imply 28.0 percent upside. The average price target from 24 Wall Street analysts of $49.08 per share imply even further upside.

Larry Robbins' Most Undervalued Stocks

In conclusion, the table below lists the seven most undervalued stocks in Glenview Capital Management's portfolio.

The Ideas section of finbox.io tracks top investors and trending investment themes. You can get the latest data on the holdings discussed above at the Glenview Capital Management page.

Managers with more than $100 million in qualifying assets under management are required to disclose their holdings to the SEC each quarter via 13F filings. Qualifying assets include long positions in U.S. equities and ADRs, call/put options, and convertible debt securities. Shorts, cash positions, foreign investments and other assets are not included. It is important to note that these filings are due 45 days after the quarter end date. Therefore, Glenview Capital Management's holdings above represent positions held as of December 31st and not necessarily reflective of the fund's current stock holdings.

However, most can agree that with thousands of stocks traded on U.S. exchanges, doing thorough research on each one is nearly impossible for smaller investors. Leveraging the resources of the largest hedge funds on Wall Street can be a powerful way to narrow down the list.

Author: Matt Hogan

Expertise: Valuation, financial statement analysis

Matt Hogan is a co-founder of finbox.io. His expertise is in investment decision making. Prior to finbox.io, Matt worked for an investment banking group providing fairness opinions in connection to stock acquisitions. He spent much of his time building valuation models to help clients determine an asset's fair value. He believes that these same valuation models should be used by all investors before buying or selling a stock.

His work is frequently published at InvestorPlace, Benzinga, ValueWalk, AAII, Barron's, Seeking Alpha and investing.com.

Matt can be reached at matt@finbox.io.

^{As of this writing, I did not hold a position in any of the aforementioned securities and this is not a buy or sell recommendation on any security mentioned.}